Elizabeth McKie

Statistics

Publications

Citations

176

H-Index

Active since

2014

Affiliations

GlaxoSmithKline (United Kingdom)(Current)

GlaxoSmithKline (United States)

Research Triangle Park Foundation

Age UK

Elizabeth McKie is an author at GlaxoSmithKline (United Kingdom) specializing in medicine, pharmacology, and pharmacokinetics of monoclonal antibodies.

Publications per year

2014–2017

Publications

A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus

Elizabeth McKie, Juliet Reid, Prafull Mistry et al. · PLoS ONE · 2016 · 80 citations · Full text

Medicine, Endocrinology, Pharmacology +17

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin- 18 mAb GSK1070806 in healthy and obese subjects

Prafull Mistry, Juliet Reid, Isabelle Pouliquen et al. · International Journal of Clinical Pharmacology and Therapeutics · 2014 · 41 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe COPD patients with ≤2% and >2% blood eosinophils

Joanna Marks-Kończalik, María J. Costa, Jon Robertson et al. · Respiratory Medicine · 2015 · 30 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +11

Biological effects of p38 MAPK inhibitor losmapimod does not translate to clinical benefits in COPD

Steven Pascoe, María J. Costa, Joanna Marks-Kończalik et al. · Respiratory Medicine · 2017 · 25 citations

Medicine, Pharmacology, Pharmacotherapy +6

1–4 of 4